Lexicon Pharmaceuticals (LXRX) Competitors $1.12 -0.03 (-2.61%) Closing price 08/7/2025 04:00 PM EasternExtended Trading$1.19 +0.07 (+6.25%) As of 04:53 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXRX vs. CLDX, DVAX, MNKD, INVA, NVAX, OPK, GERN, ZBIO, RIGL, and MYGNShould you be buying Lexicon Pharmaceuticals stock or one of its competitors? The main competitors of Lexicon Pharmaceuticals include Celldex Therapeutics (CLDX), Dynavax Technologies (DVAX), MannKind (MNKD), Innoviva (INVA), Novavax (NVAX), OPKO Health (OPK), Geron (GERN), Zenas BioPharma (ZBIO), Rigel Pharmaceuticals (RIGL), and Myriad Genetics (MYGN). These companies are all part of the "biotechnology" industry. Lexicon Pharmaceuticals vs. Its Competitors Celldex Therapeutics Dynavax Technologies MannKind Innoviva Novavax OPKO Health Geron Zenas BioPharma Rigel Pharmaceuticals Myriad Genetics Celldex Therapeutics (NASDAQ:CLDX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, profitability, risk, dividends, media sentiment, institutional ownership and valuation. Which has more risk & volatility, CLDX or LXRX? Celldex Therapeutics has a beta of 1.22, meaning that its share price is 22% more volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 1.17, meaning that its share price is 17% more volatile than the S&P 500. Which has preferable earnings & valuation, CLDX or LXRX? Celldex Therapeutics has higher earnings, but lower revenue than Lexicon Pharmaceuticals. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCelldex Therapeutics$7.02M200.56-$157.86M-$2.70-7.86Lexicon Pharmaceuticals$58.43M6.93-$200.40M-$0.33-3.39 Do institutionals & insiders have more ownership in CLDX or LXRX? 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 4.4% of Celldex Therapeutics shares are owned by insiders. Comparatively, 13.9% of Lexicon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer CLDX or LXRX? Celldex Therapeutics presently has a consensus price target of $50.11, indicating a potential upside of 136.26%. Lexicon Pharmaceuticals has a consensus price target of $3.23, indicating a potential upside of 187.95%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Celldex Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Celldex Therapeutics 0 Sell rating(s) 2 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.89Lexicon Pharmaceuticals 0 Sell rating(s) 3 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Is CLDX or LXRX more profitable? Lexicon Pharmaceuticals has a net margin of -206.43% compared to Celldex Therapeutics' net margin of -2,366.07%. Celldex Therapeutics' return on equity of -23.46% beat Lexicon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Celldex Therapeutics-2,366.07% -23.46% -22.35% Lexicon Pharmaceuticals -206.43%-80.86%-39.45% Does the media favor CLDX or LXRX? In the previous week, Lexicon Pharmaceuticals had 7 more articles in the media than Celldex Therapeutics. MarketBeat recorded 15 mentions for Lexicon Pharmaceuticals and 8 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.87 beat Lexicon Pharmaceuticals' score of 0.55 indicating that Celldex Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celldex Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryCelldex Therapeutics beats Lexicon Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Lexicon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for LXRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LXRX vs. The Competition Export to ExcelMetricLexicon PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$415.72M$2.98B$5.48B$9.57BDividend YieldN/A2.46%3.99%4.18%P/E Ratio-3.3917.9729.8725.14Price / Sales6.93262.19422.9397.17Price / CashN/A41.8335.9458.58Price / Book2.807.238.105.59Net Income-$200.40M-$54.43M$3.26B$265.48M7 Day Performance4.67%0.22%0.64%1.22%1 Month Performance22.19%5.59%2.42%0.39%1 Year Performance-33.33%9.98%27.60%23.47% Lexicon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LXRXLexicon Pharmaceuticals3.0673 of 5 stars$1.12-2.6%$3.23+187.9%-28.2%$415.72M$58.43M-3.39140Trending NewsAnalyst ForecastGap UpCLDXCelldex Therapeutics1.3855 of 5 stars$21.79-1.8%$50.11+130.0%-33.8%$1.45B$7.56M-8.07150News CoveragePositive NewsEarnings ReportDVAXDynavax Technologies4.3114 of 5 stars$11.13+2.4%$24.00+115.7%+2.9%$1.34B$277.25M-21.39350News CoverageEarnings ReportMNKDMannKind3.428 of 5 stars$3.93+4.7%$9.86+151.1%-31.5%$1.19B$285.50M39.26400Trending NewsEarnings ReportAnalyst ForecastGap UpINVAInnoviva4.3086 of 5 stars$18.61-0.1%$40.33+116.8%+1.8%$1.17B$369.84M-18.42100Positive NewsEarnings ReportNVAXNovavax4.7097 of 5 stars$6.74+2.7%$15.86+135.4%-18.0%$1.09B$682.16M2.541,990Trending NewsEarnings ReportOPKOPKO Health4.1325 of 5 stars$1.27+6.3%$2.75+117.4%-3.9%$1.00B$713.10M-5.062,997News CoverageAnalyst RevisionGERNGeron3.1366 of 5 stars$1.22+3.8%$4.61+279.5%-71.5%$773.86M$76.99M-5.79229Trending NewsEarnings ReportGap UpZBIOZenas BioPharma1.6908 of 5 stars$16.97+10.1%$36.67+116.1%N/A$709.86M$5M-4.78N/ARIGLRigel Pharmaceuticals3.3228 of 5 stars$22.71+3.6%$36.40+60.3%+208.4%$405.78M$203.08M10.97160Trending NewsEarnings ReportAnalyst ForecastMYGNMyriad Genetics3.6202 of 5 stars$3.98+1.8%$14.38+261.4%-77.1%$366.88M$837.60M-3.552,700 Related Companies and Tools Related Companies CLDX Alternatives DVAX Alternatives MNKD Alternatives INVA Alternatives NVAX Alternatives OPK Alternatives GERN Alternatives ZBIO Alternatives RIGL Alternatives MYGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LXRX) was last updated on 8/8/2025 by MarketBeat.com Staff From Our PartnersProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredCritical AI announcement set to ignite AI 2.0 A new 100% tariff on imported chips just rattled the tech sector—sending some stocks soaring and others tumbli...Timothy Sykes | SponsoredTrump’s new nightmareAccording to Porter Stansberry and Jeff Brown, a government-led financial mobilization is already reshaping Am...Porter & Company | SponsoredThe Day Silicon DiesThe Day China Left America's Supercomputers in the Dust In 200 seconds, China's quantum computer accomplish...The Oxford Club | SponsoredThis accelerated income plan is solving American's #1 retirement fearThe #1 fear in retirement today? Running out of money. That’s why income expert Tim Plaehn created a simple...Investors Alley | SponsoredSell this, buy thatWhat you don’t own matters just as much as what you do. That’s the thinking behind Eric Fry’s long-time strate...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexicon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexicon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free LXRX Stock Alerts